1. Introduction {#sec1}
===============

A large number of scientific studies have indicated prenatal substance use poses harmful health risks for the developing fetus. For example, abuse of cocaine during pregnancy exposes approximately 45,000 infants per year to cocaine in the United States alone, resulting in a wide range of neurodevelopmental impairments ([@bib42]). Confounding variables like prenatal health, frequency and intensity of cocaine use, and polydrug usage have led to contradicting reports regarding the degree and/or presence of these impairments ([@bib3]; [@bib85]; [@bib242]) yet studies that have corrected for these variables confirm that high levels of *in utero* cocaine exposure consistently lead to neurological and neurobehavioral defects ([@bib17]; [@bib47], [@bib48]; [@bib58]; [@bib167]; [@bib173]; [@bib248]). Methamphetamine (METH) usage amongst pregnant women admitted into federally-funded substance treatment facilities in the United States has increased from 8 to 24%, based on the Treatment Episode Dataset from 1994 to 2006 ([@bib239]). Notably, more than 40% of pregnant METH users reported consistent METH use throughout all three trimesters ([@bib59]). Similarly, tobacco smoking during pregnancy continues to be an important public health concern as more than half of women who are regular smokers continue to smoke throughout their pregnancies ([@bib70]). Approximately 10% of pregnant women in the United States smoke according to the Pregnancy Risk Assessment and Monitoring System (PRAMS) data, and results in more than half a million infants exposed to maternal smoking each year ([@bib246]).

The opioid epidemic is a continuing crisis in the United States; since 2014, opioid abuse has led seven states (Massachusetts, Virginia, Alaska, Arizona, Florida, Maryland, and Pennsylvania) to declare some form of public health emergency over the opioid crisis. This epidemic first emerged in the United States in the 1970s when neonatal abstinence syndrome (NAS) was first identified. NAS, also referred to as neonatal opioid withdrawal syndrome (NOWs), is characterized by withdrawal symptoms in newborns prenatally exposed to opioids such as heroin or methadone and these symptoms were identified in more than half of prenatally-exposed newborns. Common symptoms of NAS include irritability, sleep disturbances, high-pitched crying, tremors, feeding problems, projectile vomiting, diarrhea, sweating, and seizures. ([@bib43]; [@bib84]; [@bib164]).

The endoplasmic reticulum (ER), important for processing and folding of newly synthesized proteins, can trigger the ER stress response in the presence of various pathophysiological insults, including hypoxia, redox imbalance, and a variety of drugs and chemicals ([@bib44]; [@bib99]; [@bib123]; [@bib265]). Disruption in ER protein-folding homeostasis induces ER stress which subsequently activates a set of signaling pathways termed the unfolded protein response (UPR), made up of the three signaling branches IRE1, PERK, and ATF6. UPR aims to promote cell survival by reducing protein misfolding and re-establishing protein folding function in the ER via upregulation of molecular chaperones and antioxidant proteins ([@bib33]; [@bib265]). UPR can also promote apoptosis following prolonged and unresolved ER stress ([@bib152]). When ER stress in neural tissue is initiated at high intensity or for prolonged periods, it can lead to aberrant neuronal differentiation and impaired dendritic outgrowth ([@bib119]; [@bib146]). Oxidative stress is another hallmark of cellular stress and is defined as an excess of reactive oxygen species (ROS) relative to antioxidant defenses ([@bib28]). Research suggests that oxidative and ER stress are closely linked, given that protein folding in the ER requires a tightly controlled redox environment and excess ROS generation can severely affect ER homeostasis, either directly or indirectly (reviewed in [@bib158]). Crosstalk between ER stress and oxidative stress is commonly seen in neurological disorders. For example, cocaine and METH can induce neurotoxicity via ER stress and oxidative stress pathways as revealed by studies in which both acute and chronic cocaine and/or METH exposure generated reactive oxygen species and altered CNS activities in various brain subregions ([@bib19]; [@bib66]; [@bib157]; [@bib192]; [@bib275]). Similar results of imbalanced ROS and dysregulated ER stress were observed in studies examining neurotoxicity of opioids and nicotine ([@bib39]; [@bib219]; [@bib270]). Therefore, induction of ER and oxidative stress as a result of *in utero* substance exposure can be detrimental to brain development and impair neurological functions of affected infants. Despite extensive evidence from *in vitro* studies that suggest pivotal roles of ER and oxidative stress in the onset of neurodevelopmental impairments as a result of *in utero* exposure to various drugs of abuse, results from animal models and human studies have not conclusively defined mechanisms that underlie these impairments. The degree of involvement of cellular stress, including UPR, ER stress, and oxidative stress, in substance-mediated neurodevelopmental deficits remain largely unknown but has gathered great interest in the drug addiction field. In this review, we summarize *in vitro*, animal and human studies describing various drugs of abuse that are attributed to neurodevelopmental impairments, and also discuss underlying molecular and cellular mechanisms, particularly drug-induced ER and oxidative stress responses, that may potentially affect brain development of infants prenatally exposed to drugs of abuse ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Proposed cellular stress mechanisms by which prenatal drug exposure can adversely affect brain development and neurobehavioral outcomes. Psychostimulants (cocaine and METH) can elevate dopamine levels and subsequently trigger ER and oxidative stress signaling pathways or, alternatively, cocaine and METH can activate Sig-1R or cytochrome P450 and trigger ER and oxidative stress in that manner. Similarly, nicotine/NNK can induce oxidative ER stress via regulations of dopamine releases and microglial activities. Opioids can cause apoptosis and astrocytosis through ER stress-autophagy axis pathway. Cellular responses to prenatal drug exposure, including cytotoxicity, astrocytosis, microglial activation, altered neurogenesis, and synaptic plasticity, can ultimately lead to behavioral consequences of abnormal brain development. Drug-mediated pathways are depicted in designated colors. Solid arrows indicate the pathway confirmed with in vivo or *in vitro* neural models whereas dashed arrows indicate studies conducted in non-neural systems. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 1

2. Psychostimulants {#sec2}
===================

2.1. Cocaine {#sec2.1}
------------

### 2.1.1. Effects of prenatal cocaine exposure on brain development and neurobehavioral performance {#sec2.1.1}

Previous studies have indicated cocaine impacts neurobehavioral development via impaired human brain growth *in utero* ([@bib22]; [@bib194]; [@bib209]; [@bib223], [@bib222]). MRI studies have shown that prenatal cocaine exposure causes brain structural and functional abnormalities, particularly in neocortex, caudate nucleus, thalamus, cerebellum, and corpus callosum ([@bib14]; [@bib23]; [@bib68]; [@bib93]; [@bib154]; [@bib209]; [@bib281]). Notably, cocaine-induced neocortical developmental defects were shown to impair cognition, intellectual ability and functional connectivity ([@bib6]; [@bib208]; [@bib221], [@bib223], [@bib222]), language development ([@bib17]; [@bib145]; [@bib173]), and motor development ([@bib10]; [@bib166]; [@bib243]). Likewise, morphological changes in the caudate nucleus, particularly those affecting its dopaminergic neuronal input, may lead to attention deficits in later years ([@bib86]; [@bib103]; [@bib118]). Finally, interruption of thalamic development was thought to cause learning disabilities in children prenatally exposed to cocaine ([@bib90]; [@bib209]). Overall, these neuroimaging and neurobehavioral studies indicate a substantial link between *in utero* cocaine exposure and long-term central nervous system (CNS) morphological changes and their associated behavioral outcomes. Importantly, [@bib196] and [@bib194] have linked prenatal cocaine abuse with increased susceptibility for substance abuse in adolescence though mechanisms remain unknown. The continued study of cocaine-induced neural impairments is therefore crucial to better understand neurodevelopmental deficits and addictive behavior resulting from *in utero* cocaine exposure.

### 2.1.2. Cocaine-induced ER and oxidative stress in the developing brain {#sec2.1.2}

Cocaine exerts its effects on prenatal brain development via distinct pathophysiological pathways, one of which is cocaine\'s direct pharmacological effect on CNS development ([@bib27]). Monoamine transmitter (dopamine, serotonin, and noradrenaline) receptors appear during early stages of mammalian CNS development ([@bib143]), around the time monoamine axons reach the caudate nucleus and cerebral wall ([@bib144]; [@bib149]; [@bib150]; [@bib212]; [@bib257], [@bib258]; [@bib283]). Because cocaine was shown to block presynaptic reuptake of monoamine neurotransmitters ([@bib87]; [@bib269]), brain areas containing high levels of monoamine receptors, including the caudate nucleus and cortex, are more susceptible to effects of *in utero* cocaine exposure ([@bib143]; [@bib159]; [@bib163]). This in turn can impact neurotransmitter-mediated signals in those areas in early brain development ([@bib143]).

Cocaine is also suggested to affect prenatal brain development via induction of ER stress pathways. Gene profiling studies revealed that cocaine upregulated ER stress genes (BiP, CHOP, GADD34, XBP1, ATF6 and ATF4) in the striatum, medial prefrontal cortex (mPFC) and nucleus accumbens (NAcc) ([@bib188]). Specifically, acute and repeated cocaine administration induced ER stress in the rat dorsal striatum via glutamate and dopamine receptor activation, as shown by increased immunoreactivity for ER stress proteins BiP and caspase-12 following acute or repeated cocaine treatment and attenuated immunoreactivity of these ER stress proteins by NMDA antagonist MK801 and dopamine receptor D1 antagonist SCH23390 ([@bib5]). Relatedly, repeated cocaine treatment in rat dorsal striatum caused an increase in extracellular glutamate levels that was mitigated by either selective mGluR1 or mGluR5 antagonists ([@bib217]). Mechanistically, cocaine induced ER stress via glutamate receptor-mediated intracellular Ca^2+^ concentrations. This could be mediated by signaling crosstalk of group I mGluR-activated PLC/IP3 pathway, NMDA receptor-mediated Ca^2+^ influx, and group I mGluR-activated DAG/PKC pathway ([@bib49]). Together, these studies suggest that cocaine induced ER stress via glutamate and dopamine receptor activation.

In addition to monoamine neurotransmitter pathways, cocaine was shown to mediate ER stress through alternative pathways. Cocaine can bind to ER chaperone protein sigma 1 receptor (Sig-1R) and promote its dissociation from the IP~3~ receptors on the ER and translocation to the proximity of the plasma membrane. This in turn enhances calcium efflux from ER to cytosol where Ca^2+^ might influence cytoskeletal protein expression or reorganization. This suggests cocaine may mediate cytoskeletal protein dynamics of dendritic spines and participate in the malfunction of axon growth and guidance via Sig-1R-mediated ER stress pathways ([@bib101]; [@bib117]; [@bib127]; [@bib235]; [@bib250], [@bib252], [@bib249], [@bib251]). Cocaine may also mediate astrogliosis and monocyte migration in the CNS via interactions with Sig-1Rs ([@bib277]; [@bib279]).

Cocaine-induced ER stress resulted in inhibition of neural progenitor proliferation, premature neuronal differentiation, and microglial cell death *in vitro* ([@bib51]; [@bib122]; [@bib137], [@bib140], [@bib139], [@bib138]). Specifically, [@bib137] demonstrated that cocaine induced ROS-mediated ER stress via N-oxidative metabolism of cocaine in cultured neural progenitors, which subsequently downregulated *Cyclin A2* and inhibited cell proliferation via activation of the ER stress pathway PERK-eIF2α-ATF4. Pretreatment of neural progenitor cells with blockers of N-oxidative metabolism of cocaine (i.e. cytochrome P450 inhibitors SKF-525A or cimetidine) mitigated cocaine-induced ROS formation, confirming that N-oxidative metabolism of cocaine was involved in ROS generation. ROS generation also appears to be the source of cocaine-induced ER stress, as both SKF-525A and cimetidine also completely inhibited cocaine-induced ATF4 upregulation and cyclin A downregulation. The same group recently used 3D human pluripotent stem cell (hPSC)-derived cerebral organoids to identify a specific human cytochrome P450 isoform, *CYP3A5*, responsible for cocaine-induced ROS-mediated ER stress and subsequent defects in proliferation, neuronal differentiation, and organoid size in the developing human neocortex ([@bib135], [@bib138]). Notably, *CYP3A5* is polymorphically expressed in the general population, where about 60% of African-Americans but only 33% of Caucasians express active CYP3A5 while the rest have single-nucleotide polymorphisms in *CYP3A5\*3* and *CYP3A5\*6* alleles that cause a truncated form of this protein resulting in the absence of CYP3A5 activity. The polymorphic *CYP3A5* expression study together with the recent study using the human stem cell model suggest that polymorphically expressing *CYP3A5 genes* might influence responses to oxidative metabolism of cocaine and cause variability in cocaine-induced developmental defects ([@bib128]; [@bib138]). A deeper understanding of the link between genetic polymorphisms of human cytochrome P450 enzymes and cocaine-induced ER stress in the developing human brain is crucial to successfully translate research findings into clinical treatment.

The role of neuroinflammation in the onset and progression of cocaine-induced neurodevelopmental disorders is not clear. Nevertheless, a significant decrease in dopamine neurons accompanying an increase in activated microglia was observed amongst cocaine abusers ([@bib153]). Microglia act as immune cells in the brain and are involved in many aspects of development, synaptic plasticity, and neural circuitry maintenance through phagocytosis of neural precursors, newborn neurons, and synaptic elements ([@bib34]; [@bib54]; [@bib183]; [@bib262]). Disturbance of microglial activity during critical development periods may lead to defective synapses and neural circuits and higher susceptibility to neurodevelopmental disorders such as autism spectrum disorder ([@bib62]; [@bib184]; [@bib207]). Notably, ROS-mediated ER stress has been implicated in cocaine-mediated induction of microglial activation. Cocaine-induced upregulation of immune response protein TLR2 was followed by microglia activation through the ATF4-TLR2 ROS-ER stress axis *in vitro* and in a rodent model ([@bib147]). In addition, cocaine administration was shown to interrupt WNT/β-catenin signaling in the prefrontal cortex, dorsal striatum, amygdala, and nucleus accumbens of rodents ([@bib53]; [@bib65]), and alter gene expression of WNT/cadherin network in cerebral cortex of prenatally-exposed mice ([@bib181]). Microglia activation generated pro-inflammatory factors, including ROS, which interrupted neural progenitor proliferation and neuroblast formation via disruption of WNT/β-catenin signaling ([@bib129]; [@bib160]), a pathway previously linked to regulation of cell-cycle exit of neural progenitors, cortical layer formation, and cortical size determination ([@bib45], [@bib46]; [@bib134]). Together, these findings suggest that exacerbated microglia activity may contribute to neurodevelopmental deficits of prenatal cocaine exposure by interrupting WNT/β-catenin signaling. Further studies on the underlying mechanisms of cocaine-induced microglial dysregulation may prove beneficial in the identification of therapeutic targets of prenatal cocaine abuse.

Cocaine was also able to induce astrocytosis and microglial activation through crosstalk between ER stress and autophagy pathways. Pharmacological and genetic approaches revealed that cocaine-induced astrocyte and microglia activation required sequential activation of ER stress and autophagy pathways, as demonstrated by cocaine-induced increase of autophagy markers BECN1, ATG5, MAP1LC3B-II, and SQSTM1 and their involvement in PERK (also known as EIF2AK3, eukaryotic translation initiation factor 2-a kinase 3)- and IRE1 (also known as ERN1, endoplasmic reticulum to nucleus signaling 1)-mediated ER stress pathways. Reducing ROS generation mitigated cocaine-induced PERK and IRE1 activation, suggesting that ROS acts as a molecular link between cocaine exposure and ER stress pathways ([@bib95]; [@bib190]). In addition, cocaine may exert its neurotoxicity via the nitric oxide-dependent autophagic process ([@bib94]). These results suggest potential oxidative- and ER stress-mediated autophagy mechanisms for cocaine-induced neurodevelopmental deficits.

Overall, cocaine-induced ER and oxidative stress seem to mediate several distinct pathophysiological pathways, including neuroinflammation via microglial activation, cytoskeletal dynamics via Sig-1R, and impaired cell proliferation and differentiation via N-oxidative metabolism of cocaine. Further research is necessary to continue to elucidate a link between the aforementioned pathways and how they may lead to prenatal neurodevelopmental defects as well as discovering potential new pathways by which cocaine may exert its impact.

2.2. Methamphetamine {#sec2.2}
--------------------

### 2.2.1. Effects of prenatal methamphetamine exposure on brain development and neurobehavioral performance {#sec2.2.1}

MRI scans of adolescents prenatally exposed to METH showed significant changes in brain structure and cognitive performance, including reduced volumes of the caudate, thalamus, putamen, globus pallidus, and hippocampus, changes in white matter connections, and correlated deficits in attention and verbal memory ([@bib41], [@bib40]; [@bib267], [@bib268]). A similar study found that prenatal METH exposure led to cognitive deficits in adolescents as a result of striatal volume reductions ([@bib232]). Interestingly, [@bib205] reported enlargement of putamen in METH-exposed pre-adolescent children which, when taken together with previously mentioned studies ([@bib41]; [@bib232]), suggests a potential neuropathology pattern of aberrant brain growth followed by slowed growth and impaired brain development. This atypical pattern has been previously reported in children suffering from autism spectrum disorder ([@bib7]; [@bib52]). Thus, further longitudinal studies are necessary to precisely elucidate mechanisms of brain volume changes, especially in dopamine-rich brain regions, and their associated neurodevelopmental impacts in children with prenatal METH exposure.

### 2.2.2. Methamphetamine -induced ER and oxidative stress in the developing brain {#sec2.2.2}

Similar to cocaine, METH exerts its reinforcing effects mainly via an interaction with the mesolimbic dopamine reward system by blocking dopamine reuptake ([@bib12]; [@bib260]). However, METH can also stimulate release of cytoplasmic dopamine from presynaptic neurons into extracellular space ([@bib74]; [@bib218]) which is supported by studies showing METH causes greater dopamine release than cocaine in basal ganglia ([@bib285]). In addition to having different biochemical mechanisms of action, METH and cocaine yield different neurotoxic effects on the brain. METH was reported to cause extensive neurotoxicity on dopamine terminals in the striatum ([@bib11]; [@bib73]; [@bib261]) that can produce long-lasting striatal dopamine depletion and destruction of dopaminergic terminals in abusers. Moreover, METH can also induce neuronal apoptosis in the striatum ([@bib60]; [@bib61]; [@bib287]). In contrast, cocaine administration did not elicit neurotoxic effects as severe as METH ([@bib125]; [@bib206]). *In vitro* studies with fetal rat primary neuronal culture indicated that METH was neurotoxic to cultured mesencephalic dopamine cells as evidenced by impairments in dopamine reuptake and reduction in tyrosine hydroxylase (TH) and neuron-specific enolase immunostaining. Contrarily, cocaine neither impaired neuronal function nor altered dopamine cell survival in these cultures ([@bib24], [@bib25]). These findings indicate that various illicit stimulants can perturb dopaminergic function via different biochemical mechanisms and with varying neurotoxic potencies and suggests that METH mechanisms other than reuptake inhibition may be responsible for METH-induced neuronal damage.

Increase in dopamine levels following METH administration has been linked to enhanced oxidative stress ([@bib38]; [@bib111]). Augmented dopamine levels can lead to generation of free radical species including superoxide and hydrogen peroxide, derived from auto-oxidation of dopamine or enzymatic oxidation by monoamine oxidase ([@bib274]). METH-induced oxidative stress has been shown to cause striatal neuronal apoptosis via ER stress pathways, as shown by increased activity of proteases calpain and caspase-12 and upregulation of ER stress proteins BiP/GRP78, CHOP/GADD153, or Trib3 in rodent brains following METH injections ([@bib113]; [@bib273]). Several METH-responsive ER genes have been identified ([@bib114]; [@bib21]) and the upregulation of these genes were blocked by D1 and D2 receptor antagonist SCH23390 ([@bib21]). METH and cocaine both activate ER stress in the striatum yet they differ in their capacity to induce cell death ([@bib5]; [@bib113]; [@bib217]). METH generates greater neurotoxicity to striatal neurons compared to cocaine ([@bib60]; [@bib61]; [@bib125]; [@bib206]; [@bib287]) yet the mechanism with which METH- or cocaine-induced ER stress promotes apoptosis or cytoprotection in striatal neurons remains unknown. One potential explanation is that excess dopamine released after METH administration might activate apoptotic machinery in striatal neurons once ER stress cannot be remedied. In contrast, cocaine releases smaller quantities of dopamine which might activate survival mechanisms that would prevent apoptosis in ER-stressed cells.

Sig-1R chaperones at the ER-mitochondrion interface were upregulated in rodent brains following METH self-administration and have been implicated in METH\'s adverse effects on the brain ([@bib100]; [@bib199]; [@bib233]). METH interacts with Sig-1Rs at physiologically relevant levels and blockage of Sig-1Rs can mitigate METH-induced neurotoxicity, striatal dopamine depletion, striatal dopamine transporter downregulation, locomotor stimulation, memory deficiencies, and hyperthermia, though the neuroprotective mechanisms remain unknown ([@bib162]; [@bib179]; [@bib200]; [@bib214]). Moreover, pretreatment with a Sig-1R antagonist can attenuate METH-induced microglial activation and upregulation of proinflammatory cytokines in the striatum ([@bib201]). Previous studies have indicated that microglia activation leads to generation of reactive species that help orchestrate METH-induced neurotoxicity ([@bib132]; [@bib240]; [@bib241]). Thus, further exploration of Sig-1R antagonists may shed light on better pharmacological protection against METH-induced neurotoxicity and neurobehavioral changes.

METH exposure has also been associated with altered astrocytic functions. Oxidative stress coupled with reactive astrogliosis in the striatum is an indication of METH toxicity ([@bib91], [@bib92]; [@bib286]). During CNS development, astrocytes play a role in neuronal differentiation, migration, synaptogenesis, myelination, and activity-dependent synaptic plasticity ([@bib50]; [@bib80]; [@bib102]; [@bib110]; [@bib169]). Impairments in astrocyte function can therefore negatively impact neuronal development and precise formation of neural circuitry necessary for proper CNS function ([@bib120]; [@bib189]; [@bib230]; [@bib231]; [@bib234]). In addition, cytochrome P450 2E1 (CYP2E1) which is expressed and catalytically active in the human brain ([@bib79]; [@bib106]; [@bib133]; [@bib172]; [@bib244]; [@bib254]), can be induced by METH in cultured human astrocytes ([@bib216]). The authors demonstrated that METH can induce ROS-mediated apoptosis of astrocytes via a NADPH oxidase-coupled CYP2E1-dependent pathway, suggesting that CYP2E1 effects on astrocytes may contribute in part to METH neurotoxicity on the developing brain. Genetic polymorphisms in *CYP2E1* might also alter enzymatic activity and alter effects of METH-induced oxidative stress in astrocytes ([@bib165]). A clearer understanding of inter-individual variability of *CYP2E1* in response to METH could lead to identification of factors contributing to astrocytic dysfunction in the striatum against METH.

2.3. Tobacco {#sec2.3}
------------

### 2.3.1. Effects of prenatal tobacco exposure on brain development and neurobehavioral performance {#sec2.3.1}

Tobacco smoke contains numerous chemicals including nicotine, hydrogen cyanide, carbon monoxide, nitrosamines, polycyclic aromatic hydrocarbons, benzene, etc, many of which cause harmful effects to the central nervous, cardiovascular, and pulmonary systems. In this section, we review key findings focusing specifically on effects of nicotine and tobacco-specific nitrosamines.

As shown by neuroimaging studies, prenatal tobacco exposure leads to abnormalities in brain morphology and function, including cortical gray matter volume reduction, coherent anterior corona radiata fibers and thinning of the superior frontal, superior parietal, and precentral cortical areas in children ([@bib40]; [@bib71], [@bib72]; [@bib197]). Notably, these prenatally-exposed children exhibited more emotional problems compared to healthy controls, likely due to thinning of the superior frontal and precentral cortices ([@bib71]). Another set of studies assessed adolescents whose mothers smoked during pregnancy and identified similar cortical thinning, particularly in orbitofrontal, middle frontal, and parahippocampal cortices and interestingly, females were more severely affected than males ([@bib247]). The orbitofrontal cortex plays a significant role in antisocial behavior, impulsivity, and cue-mediated drug intake ([@bib31]; [@bib76]; [@bib203], [@bib204]; [@bib213]). Prenatal tobacco exposure can hinder development of the orbitofrontal cortex and in turn lead to alterations in social behavior and increase susceptibility to drug use in adolescence ([@bib155]; [@bib247]). Prenatal tobacco exposure also caused a reduction in pallidum and amygdala volumes ([@bib97]; [@bib154]) and in the size of the corpus callosum, which is the fiber tract connecting the two cerebral hemispheres ([@bib187]). Interestingly, only females exhibited smaller corpus callosum, particularly in its posterior part. Posterior corpus callosum contains interhemispheric fibers forming ventral and dorsal visual streams ([@bib104]; [@bib186]) and tobacco-induced reduction in posterior corpus callosum impaired visual attention ([@bib75]; [@bib112]). Taken together, these findings suggest prenatal tobacco exposure can negatively affect cortical development and expands our knowledge of the causal relationship between brain structure and behavior; however, further research is necessary to elucidate precise mechanisms underlying these structural impairments.

### 2.3.2. Tobacco-induced ER and oxidative stress in the developing brain {#sec2.3.2}

Nicotine, the primary psychoactive component of tobacco, binds to nicotinic acetylcholine receptors (nAChRs) expressed in neural progenitors during early embryonic cortical development ([@bib13]). Cholinergic neurons innervate the cerebral cortex during a critical period of neuronal differentiation and synaptogenesis, and acetylcholine, as a neuromodulator, can modulate the growth, differentiation, and plasticity of developing cortical neurons ([@bib105]; [@bib130]; [@bib191]). Sustained exposure to nicotine can hinder progenitor self-renewal and promote premature neuronal differentiation via activation of α4β2 nicotinic acetylcholine receptors (α4β2-nAChRs), as shown *in vitro* with primary neural progenitors derived from fetal rodent neocortex ([@bib236]). In animal models, over-stimulation of nAChRs by nicotine during gestation seems to alter nAChR expression and disrupt cortical development, specifically targeting neural progenitor division and differentiation, synaptic development, and synaptic activity, ultimately resulting in cognitive and executive control impairments in children with prenatal tobacco exposure ([@bib9]; [@bib16]; [@bib35]; [@bib175]; [@bib176]; [@bib185]; [@bib225]; [@bib226]; [@bib227]). Therefore, prenatal nicotine exposure disturbs trophic effects of acetylcholine on cell proliferation, neuronal differentiation, and synaptic development that are required for proper assembly of the brain.

Nicotine can induce oxidative stress in multiple brain regions, including prefrontal cortex, striatum, hippocampus, and cerebellum ([@bib29]; [@bib36]; [@bib56]; [@bib193]), and increased oxidative stress may underlie some of the adverse effects on brain development caused by prenatal nicotine exposure. Stimulation of nAChRs by nicotine resulted in dopamine release in prefrontal cortex and striatum ([@bib26]; [@bib55]), and this excess dopamine may lead to generation of free radicals. Furthermore, [@bib56] showed that nicotine inhibited mitochondrial electron transport chain complexes and produced nitric oxide, subsequently repressing mitochondrial oxidative stress scavenger systems in the brain and causing lipid peroxidation and protein oxidation in the mitochondria of several brain regions. Notably, increased nitric oxide induced by nicotine was shown to inhibit proliferation of mouse neural stem cells through upregulation of histone deacetylase 1 (HDAC1) ([@bib141]), a protein involved in epigenetic regulation of neurogenesis in the developing brain ([@bib171]). Furthermore, *in vitro* studies have demonstrated that nicotine inhibited proliferation of neural progenitors through induction of oxidative stress ([@bib193]). These results suggest that nicotine-induced oxidative stress and nitric oxide production might elicit neurotoxicant actions in the developing brain.

As of yet, no evidence links prenatal nicotine exposure to ER stress in the developing brain; however, oxidative stress induced by prenatal nicotine exposure might indirectly lead to ER stress activation and subsequently contribute to the observed neurodevelopmental deficits. For example, [@bib195] showed that nicotine inhibited proliferation of human trophoblast cells via ROS-mediated ER stress responses. Moreover, prenatal nicotine exposure in rodents impaired placental function through activation of ER stress pathway ([@bib271]).

Astrocytes contain high amount of ROS scavenger molecules which protect astroglial cells against deleterious effects of ROS and promote neuronal survival ([@bib63]; [@bib69]; [@bib81]; [@bib82]). Astrocytes participate in the defense of surrounding neurons by providing prosurvival trophic factors and antioxidant molecules such as glial cell-line derived neurotrophic factor (GDNF) and glutathione precursors ([@bib98]; [@bib151]; [@bib161]; [@bib211]). [@bib98] recently demonstrated that cultured astrocytes isolated from newborn rats prenatally exposed to tobacco were more vulnerable to oxidative insult than astrocytes isolated from control animals, indicating that despite their high antioxidant capacity, astrocytes derived from prenatally-exposed animals could not survive under increased oxidative stress, and the loss of antioxidative ability of astrocytes following tobacco exposure may partially explain the brain\'s susceptibility to additional oxidative stress and its progression towards developmental dysfunction.

4-Methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific procarcinogen, can activate microglia in the mouse brain and cause neuronal damage ([@bib89]). In contrast to nicotine-induced oxidative stress occurring in microsomes and mitochondria of rat brain, NNK-induced oxidative damage occurred predominantly in the brain microsomes ([@bib29]). Notably, expression of microsomal CYP2E1, involved in the metabolic activation of NNK in humans ([@bib1]; [@bib228]; [@bib276]), was greatly increased in brains of monkeys and rats following nicotine exposure ([@bib8]; [@bib115], [@bib116]). These findings indicated that nicotine-induced CYP2E1 upregulation in the brain may influence onset or progression of tobacco-mediated neurodevelopmental defects. Taken together, the understanding of the interface between oxidative stress, ER stress, and microglial inflammation is important to develop therapeutic strategies to prevent neurodevelopment abnormalities *in utero* after exposure to tobacco.

2.4. Opioids {#sec2.4}
------------

### 2.4.1. Effects of prenatal opiate exposure on brain development and neurobehavioral performance {#sec2.4.1}

Assessments of prenatal opioid exposure in children and modeling prenatal opioid exposure in animals have provided insights on the effects of NOWs on neurobehavioral functioning of neonates. In animal studies, prenatal opioid exposure is correlated with lower birth weights, reduced brain mass, increased depressive-like behavior, craniofacial anomalies, and higher mortality rate ([@bib37]; [@bib64]; [@bib108]; [@bib109]; [@bib224]; [@bib272]). In humans, prenatal opioid exposure can lead to various adverse health problems in infants, longer hospital stays, and a higher rate of admission to intensive care units ([@bib124]; [@bib245]).

In animal models, prenatal exposure to opioid is associated with abnormal CNS function including dysregulated cholinergic activity, delayed neural tube defects, decreased myelination, impaired memory performance, impaired fear memory extinction and hippocampal CA1 synaptic plasticity, enhanced activity of blood-brain barrier transport system of opiate peptides, delayed development of monoamine oxidase isoforms, decreased brain volume, and altered neurochemistry ([@bib18]; [@bib178]; [@bib198]; [@bib210]; [@bib237]; [@bib253]; [@bib282]).

Human neuroimaging studies examining early cerebral connective tract development showed that methadone-exposed infants demonstrated higher mean diffusivity in the superior longitudinal fasciculus regionally ([@bib264]) and reduced fractional anisotropy and altered microstructure in major white matter tracts ([@bib170]). Moreover, information processing deficits were observed in young boys as a result of *in utero* exposure to methadone ([@bib96]). Prenatal opioid exposure (methadone, buprenorphine, or heroin) may also be associated with brain volume reduction and subsequent cognitive and behavioral deficits ([@bib263]; [@bib280]). Studies have documented that prenatal opioid exposure, specifically methadone and buprenorphine, impairs cognitive development in early childhood ([@bib20]; [@bib126]; [@bib229]; [@bib255]; [@bib256]). Additionally, a longitudinal study suggesting prenatal opioid exposure reduced IQ scores, with male subjects demonstrating poorer cognitive functions than female subjects ([@bib182]).

Although there remain inconsistencies amongst studies, perhaps partly due to limited sample sizes, study populations, varied analytical approaches and/or experimental designs, these results strongly suggest that opioid-exposed infants are more likely to develop cognitive and behavioral difficulties. Collectively, these studies raise concerns on the potential effects of prenatal opioid exposure on cognitive development and performance. Further investigation of opioids' effects on prenatal brain development are warranted.

### 2.4.2. Opioid-induced ER and oxidative stress in the developing brain {#sec2.4.2}

Although strong evidence suggests prenatal opioid exposure leads to various neurobehavioral defects later in life, the underlying neurobiological mechanisms remain unelucidated. Prenatal opioid exposure may lead to depressive-like behavior due to imbalanced oxidative stress. For example, rat pups exposed to high doses of buprenorphine (1 mg/kg/day) during gestation exhibited elevated oxidative stress as shown by increased lipid peroxidation levels and reduced glutathione (GSH) levels and glutathione activity. High doses of buprenorphine also impaired expression and activation of key neurotrophin signaling factors, including reduced plasma BDNF and serotonin levels, reduced ERK and TrkB phosphorylation, and impaired protein kinase A activity ([@bib108]). These results were supported by a separate study that noted reduced BDNF expression and impaired neurogenesis in prenatal buprenorphine-exposed rat pups ([@bib272]). These studies collectively propose a potential mechanism underlying *in utero* opioid exposure and development of depressive-like behavior.

Prenatal exposure to buprenorphine may also affect myelin formation during brain development. Oligodendrocytes are myelinating cells found in the CNS and oligodendrocyte-regulated myelination provides valuable support to axonal function, synaptic plasticity, and CNS injury repair that are critical for proper CNS development and function ([@bib32]; [@bib83]; [@bib168]; [@bib210]; [@bib220]). [@bib210] examined effects of buprenorphine on myelination and found that high doses of buprenorphine (1 mg/kg/day) during gestation reduced expression of myelin basic protein splicing isoforms during CNS development. Although prenatal exposure to buprenorphine increased the caliber of myelinated axons, thinner myelin sheaths were observed in these axons.

Prenatal heroin and morphine exposure were both found to induce apoptosis and impair learning and memory ([@bib178], [@bib177]; [@bib266]). For example, hippocampi from mice exposed to heroin (10 mg/kg/day) during gestation exhibited elevated protein and mRNA levels of apoptotic markers caspase-3 and Bax, and reduced levels of anti-apoptosis marker Bcl-2. Caspase-3 was significantly activated in the dentate gyrus (DG) and CA1 of the hippocampus in postnatal animals. Prenatal heroin exposure may consequently impair short-term spatial memory later in life, as shown by decreased dendritic arborization in cortical layers II and III and poor performance in location preference tasks ([@bib156]).

Similarly, prenatal morphine exposure led to neuronal loss and memory impairments in rat embryos; they were smaller in size, displayed neural tube deficits between E9.5 and E13.5 ([@bib178]), and exhibited increased apoptosis throughout the CNS ([@bib177]). Specifically, [@bib88] reported that prenatal exposure to morphine reduced pyramidal neuron density in mouse hippocampus which offers an explanation for postnatal learning and memory task deficits. Prenatal morphine exposure may also impair memory performance via long-term depression (LTD) and cytoskeletal network rearrangements, as suggested by reports of impaired synaptic plasticity in DG, reduced BDNF levels, and reduced expression of postsynaptic marker PSD95 and neuronal nitric oxide synthase (nNOS) in postnatal rat pups exposed to morphine prenatally ([@bib180]; [@bib278]) Prenatal morphine exposure may also affect brain development by lowering activity of brain cyclin-dependent kinase 5 (Cdk5) in embryos. Interestingly, prenatal cocaine exposure exhibited the opposite effect on Cdk5 activity, and co-administration of cocaine and morphine tended to obliterate their individual effects on Cdk5 activity ([@bib30]). These data suggested prenatal exposure to heroin or morphine during embryonic neurogenesis may disturb apoptotic pathways and pose long-term impacts on postnatal learning and memory defects.

Recent studies have shed light on ER stress-integrated mechanisms of opioid-mediated impairments on brain development and cognitive functions. [@bib219] revealed morphine exposure induced astrocytosis and subsequent inflammatory responses via ER stress-autophagy axis. Morphine exposure not only resulted in upregulation of the ER chaperone BiP, also led to induction of autophagy and autophagasome accumulation as indicated by elevated autophagy markers BECN1, LC3-II, and p62. Morphine-impaired ER-autophagy axis further induced proinflammatory cytokine production in a mu opioid receptor (MOR)-dependent fashion. The study also showed morphine induced profound astrocytosis in the cerebellum of rhesus macaques. Similarly, morphine exerted detrimental synaptic regulations via sequential induction of ROS, ER stress, and autophagy in the hippocampus. Morphine-mediated MOR activation induced NADPH oxidase-mediated ROS generation, activated ER stress (pPERK, IRE1α, and ATF6) and autophagy (Beclin1, ATG5/ATG7, and LC3-II), and eventually led to synaptic density alterations that can contribute to cognitive disabilities ([@bib39]). These findings suggested ER stress crosstalk plays a pivotal role in morphine-mediated neuroplasticity.

Emerging studies also suggest that ER and oxidative stress regulate morphine tolerance ([@bib2]; [@bib67]; [@bib131]; [@bib174]). Repeated morphine exposure leads to development of morphine tolerance ([@bib202]) which might partially be controlled by ER and oxidative stress signaling pathways, including ER stress-mediated glycogen synthase kinase 3beta (GSK-3β) activation ([@bib67]). Phosphoproteomic analyses of morphine-tolerant rat spinal cords revealed potential underlying mechanisms that contribute to the development of morphine tolerance, including ER stress, mitochondrial dysfunction, cytoskeleton reorganization, receptor trafficking, and biomolecular metabolism ([@bib148]).

Reports have also indicated morphine-induced apoptosis in microglia, neurons, and astrocytes ([@bib57]; [@bib107]). Other opioids, including oxycodone, tramadol, and tapentadol, were reported to induce oxidative stress and ER stress in various brain regions ([@bib15]; [@bib77]; [@bib78]; [@bib288]). On the contrary, morphine reduced astrocyte apoptosis upon cytotoxic insults ([@bib121]; [@bib142]). A recent study demonstrated morphine exerted a protective effect in response to glutamate-stimulated apoptosis of spinal cord astrocytes and did so via reducing calcium overloading and suppressing ER stress sensors ([@bib284]). Interestingly, the opioid antagonist naloxone was also found to cause apoptosis and induce multiple ER chaperones (BiP, ERp29 and PDI) and ER stress sensors (ATF-6, IRE1, and PERK) *in vitro* ([@bib215]).

3. Concluding remarks {#sec3}
=====================

The continued rise of drug abuse-related deaths necessitates improved therapies to treat drug addictions in combination with revised laws and policies to control distribution of addictive substances. Prenatal drug exposure can cause neurodevelopmental deficits and lead to neurobehavioral changes, although each substance can induce ER and oxidative stress via different pathways and no addiction scenario is the same. Thus, when it comes to addiction therapies, "one treatment fits all" simply does not work; many studies are instead supporting the concept of personalized medicine to revolutionize the treatment plan for drug addiction.

While methadone and buprenorphine are commonly used detoxification drugs to wean off opioid addiction, clinical studies have indicated that patients often develop drug dependency after extended treatment periods. This poses additional challenges for opioid abuse treatments and necessitates the development of alternative strategies to cope with the ongoing opioid crisis. In addition to improving postnatal care for substance-exposed newborns, more actions should be taken to mitigate adverse outcomes of infants born to mothers with opioid and other substance use disorders during pregnancy. For instance, enriched environments and increasing exercises are both proven to improve cognitive functions of prenatally-exposed children ([@bib4]). Treatments with platelet derived growth factor (PDGF) ameliorated morphine-induced ROS productions and restored spine densities ([@bib39]). Furthermore, dextromethorphan, an active ingredient found in cough syrup, may be repurposed as a mitigator of adverse opioid effects during gestation and lactation periods since co-administration of dextromethophen with morphine were found to significantly attenuate morphine-induced neurologic effects ([@bib238]; [@bib278]).

Recently, the National Institute on Drug Abuse embarked on a 10-year longitudinal study of adolescent brain cognitive development (ABCD Study) to observe factors that affect brain growth. The multi-institute collaborative research project is expected to bring forth valuable information ([@bib259]). Animal studies suggested that many alterations of neuronal activity occurred in infants during the first two weeks after birth, a period which was shown to be critical for proper brain development and which should be a primary focus for any interventions aimed at reducing brain damage cause by prenatal drug exposure. For long-term therapeutic strategies, the ABCD Study should serve as a research model with which to implement systematic evaluation and longitudinal monitoring on cognitive function and neurobehavioral outcomes of children with prenatal substance exposure. Since details of ER and oxidative stress mechanisms affecting brain development is scarce, further studies on the cellular pathways contributing to drug-induced behavioral and neurocognitive impairments would be greatly beneficial to effectively develop new therapeutic strategies.
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